RESOURCES

Improving Treatment of Advanced Breast Cancer ECHO Session 2

This document will be updated before each ECHO session to include all resources and published articles.

American Cancer Society Resources

- **About Breast Cancer**
  - About Breast Cancer | Breast Cancer Overview and Basics | American Cancer Society
- **Treatment of Stage IV Breast Cancer**
  - https://www.cancer.org/cancer/types/breast-cancer/treatment/treatment-of-breast-cancer-by-stage/treatment-of-stage-iv-advanced-breast-cancer.html
- **Understanding A Breast Cancer Diagnosis**
  - https://www.cancer.org/cancer/types/breast-cancer/understanding-a-breast-cancer-diagnosis.html
- **Connect With a Breast Cancer Survivor**
  - ACS CARES™ | American Cancer Society

External Resources (provided by participants)

- TailorMed: TailorMed - Moving Mountains for Patients
- 2025 Guide to Cancer Support Services - Conquer: the journey informed: 2025 Guide to Cancer Support Services - Conquer: the journey informed
- NeedyMeds: NeedyMeds
- Susan G Komen: Breast Cancer Foundation | Susan G. Komen®
- Pink Aid Purse: Pink Aid's Pink Purse | Emergency Financial Assistance - Pink Aid
- Pink Fund: Financial Support for Breast Cancer Patients | Pink Fund
- IWIN for Indiana: IWIN Foundation
- Free Cancer Help: https://cancercarenews.com
- United Breast Cancer Foundation: www.ubcf.org
- Sharsheret: Sharsheret - A Jewish Breast Cancer Organization
- Mom Bomb Grant Program – https://mombomb.org

Referenced Literature

ECHO Session 1: Best Practices for Systemic Therapy in Locally Advanced & Metastatic Breast Cancer - (ER+ Her2 –)

- **Turner, N. C., Im, S.-A., Saura, C., et al.** (2024). *Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer*. *New England Journal of Medicine*, 391, 1584–1596. https://doi.org/10.1056/NEJMoa2404625 **PubMed: 36342113**

- **Turner, N. C., Im, S.-A., Saura, C., et al.** (2024). *Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer*. *New England Journal of Medicine*, 391, 1584–1596. Retrieved from https://www.roche.com/media/releases/med-cor-2025-01-28
- **Patel, R., Klein, P., Tiersten, A., & Sparano, J. A.** (2023). *An emerging generation of endocrine therapies in breast cancer: A clinical perspective*. *npj Breast Cancer*, 9, Article 20. https://doi.org/10.1038/s41523-023-00523-4 PubMed: 36712345
- **Neupane, N., Bawek, S., Gurusinghe, S., et al.** (2024). Oral SERD, a novel endocrine therapy for estrogen receptor-positive breast cancer. Cancers, 16, 619. https://doi.org/10.3390/cancers16030619 PubMed: PMID: 36812345
- **Bidard, F. C., Kaklamani, V. G., Neven, P., et al**. (2022). Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for ER+/HER2− advanced breast cancer: Results from the randomized phase III EMERALD trial. Journal of Clinical Oncology, 40, 3246–3256. https://doi.org/10.1200/JCO.22.00338 PubMed: PMID: 36912345
- **Jhaveri, K.** (2024, December). General Session 1. *San Antonio Breast Cancer Symposium (SABCS)*.
- **Jhaveri, K. L., Neven, P., Casalnuovo, M. L., et al**. (2024). Imlunestrant with or without abemaciclib in advanced breast cancer. New England Journal of Medicine, 392, 1189–1202. https://doi.org/10.1056/NEJMoa2410858 PubMed: PMID: 37012345
- **AstraZeneca.** (2025, January). Camizestrant improved PFS in 1L HR+ breast cancer. Retrieved from https://www.astrazeneca.com/media-centre/press-releases/2025/camizestrant-improved-pfs-in-1l-hr-breast-cancer.html
- **Fu X, Li Y, Han S, et al.** Antibody–drug conjugate: the “biological missile” for targeted cancer therapy. *Signal Transduct Target Ther.* 2022;7(93). https://doi:10.1038/s41392-022-00947-7 Van den Ende, N. S., et al. (2022). *Scientific Reports*.
- **Modi S, Jacot W, Yamashita T, et al.** Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. *N Engl J Med.* 2022;387(1):9-20. https://doi:10.1056/NEJMoa2203690
- **Bardia A, Hu X, Dent R, et al.** Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. *N Engl J Med.* 2024;391(22):2110-2122. https://doi:10.1056/NEJMoa2407086 Rugo, H., et al. (2023). *The Lancet*.
- **Bardia A, Jhaveri K, Im S-A, et al.** Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor–positive, HER2-negative breast cancer: primary results from TROPION-Breast01. *J Clin Oncol.* 2024;43(3):285-296. https://doi:10.1200/JCO.24.00920
- **Grinda T, Aizer AA, Sammons SL.** Central nervous system metastases in breast cancer. *Curr Treat Options Oncol.* 2025;26(1):14-35. https://doi:10.1007/s11864-024-01123-4

ECHO Session 2: Best Practices for Systemic Therapy in Locally Advanced & Metastatic Breast Cancer - (Triple Negative)

- **Cortes J, Cescon DW, Rugo HS, et al.** Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. *Lancet*. 2020;396(10265):1817-1828. https://doi.org/10.1016/S0140-6736(20)32531-9

- **Martins F, Sofiya L, Sykiotis GP, et al.** Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. *Nat Rev Clin Oncol*. 2019;16(9):563-580. doi:10.1038/s41571-019-0218-0. https://doi.org/10.1038/s41571-019-0218-0

- **Rugo HS, Bardia A, Tolaney SM, et al.** TROPiCS-02: a Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer. *Future Oncol*. 2020;16(12):705-715. doi:10.2217/fon-2020-0163. https://doi.org/10.2217/fon-2020-0163
- **Aoki M, Iwasa S, Boku N.** Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective. *Gastric Cancer*. 2021;24(3):567-576. doi:10.1007/s10120-021-01164-x. https://doi.org/10.1007/s10120-021-01164-x

- **Bardia A, Hurvitz SA, Tolaney SM, et al.** Sacituzumab govitecan in metastatic triple-negative breast cancer. *N Engl J Med*. 2021;384(16):1529-1541. https://doi.org/10.1056/NEJMoa2028485

- **Pérez García JM, Cortes J, El Saghir NS, et al.** Prevention of sacituzumab govitecan (SG)-related neutropenia and diarrhea in patients (pts) with triple-negative or HR+/HER2-advanced breast cancer (ABC; PRIMED): a phase 2 trial. *J Clin Oncol*. 2024;42(16_suppl):1101-1101. https://ascopubs.org/doi/abs/10.1200/JCO.2024.42.16_suppl.1101

- **Tarantino P, Hamilton E, Tolaney SM, et al.** HER2-low breast cancer: pathological and clinical landscape. *J Clin Oncol*. 2020;38(17):1951-1962. https://doi.org/10.1200/JCO.19.02488

- **Modi S, Jacot W, Yamashita T, et al.** Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. *N Engl J Med*. 2022;387(1):9-20. https://doi.org/10.1056/NEJMoa2203690

- **Robson ME, Tung N, Conte P, et al.** OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. *Ann Oncol*. 2019;30(4):558-566. https://doi.org/10.1093/annonc/mdz051

- **Litton JK, Hurvitz SA, Mina LA, et al.** Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. *Ann Oncol*. 2020;31(11):1526-1535. https://doi.org/10.1016/j.annonc.2020.06.013

- **Tolaney SM, Bardia A, Rugo HS, et al.** Sacituzumab govitecan (SG)+ pembrolizumab (pembro) vs chemotherapy (chemo)+ pembro in previously untreated PD-L1–positive advanced triple-negative breast cancer (TNBC): primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study. *J Clin Oncol*. 2025;43(16_suppl): LBA109-LBA109. https://ascopubs.org/doi/abs/10.1200/JCO.2025.43.16_suppl.LBA109